AdaptHealth Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AHCO research report →
Range $8 – $13
Price Chart
About the company
AdaptHealth Corp. , alongside its network of subsidiaries, delivers a comprehensive range of home medical equipment (HME), supplies, and associated services across the United States. The company specializes in sleep therapy, providing CPAP and bi-PAP devices and support for individuals managing obstructive sleep apnea.
- CEO
- Suzanne Foster
- IPO
- 2018
- Employees
- 10,900
- HQ
- Conshohocken, PA, US
Get TickerSpark's AI analysis on AHCO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $982.98M
- P/E
- -2.47
- Fwd P/E
- 86.28
- PEG
- 0.03
- P/S
- 0.32
- P/B
- 0.82
- EV/EBITDA
- 36.87
- Div Yield
- 0.00%
- Gross Margin
- 15.31%
- Op Margin
- -7.38%
- Net Margin
- -12.90%
- ROE
- -28.90%
- ROIC
- -6.02%
Latest fiscal year · YoY change
- Revenue
- $3.24B-0.5%
- Gross Profit
- $568.56M-16.5%
- Op Income
- $186.27M
- Net Income
- $-70,794,000-178.3%
- EPS
- $-0.52-183.9%
- OCF Growth
- +11.1%
- FCF Growth
- -7.0%
- 52W High
- $13.43
- 52W Low
- $5.21
- 50D MA
- $6.30
- 200D MA
- $8.99
- Beta
- 1.36
- RSI (14)
- 57
- Avg Volume
- 2.56M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AdaptHealth beat third-quarter expectations on revenue, EBITDA and cash flow as its largest capitated contract turned profitable, while the company raised full-year revenue and EBITDA guidance but trimmed free cash flow guidance.· November 3, 2026
- Net revenue was $745.6 million, up 10.9% year over year and 12.8% organically; adjusted EBITDA was $141.9 million, down from $146.1 million a year ago but above guidance.
- The largest capitated contract swung to a positive contribution in Q3, with about 10% margin in the quarter and a run rate near 14% exiting the quarter.
- Management raised full-year guidance for net revenue to $2.88 billion-$2.9 billion and adjusted EBITDA to $510 million-$525 million.
- Free cash flow was $51.1 million in Q3, slightly ahead of plan, but full-year free cash flow guidance was lowered to $55 million-$80 million.
- The Diabetes Health sale to Cardinal remains on track to close early in 2027, and Medline bed replacement/repair is being treated as manageable so far.
- The company highlighted traction in enterprise sales, new capitated wins for 72,000 lives, and continued growth in the MyAPP digital platform.
Third-quarter net revenue was $745.6 million, up 10.9% year over year and 12.8% organically. Adjusted EBITDA was $141.9 million versus $146.1 million in the prior-year quarter, with margin at 19% versus 21.7% a year ago. Free cash flow was $51.1 million, slightly ahead of guidance, and reported net loss attributable to AdaptHealth was $168.2 million, driven mainly by a $184.8 million non-cash goodwill impairment charge. For the full year, the company raised net revenue guidance to $2.88 billion-$2.9 billion and adjusted EBITDA guidance to $510 million-$525 million; fourth-quarter guidance implies net revenue of about $715 million-$735 million and adjusted EBITDA of about $130 million-$145 million. Full-year free cash flow guidance was lowered to $55 million-$80 million, with fourth-quarter free cash flow expected at roughly $50 million-$75 million.
Suzanne Foster said the quarter marked a “step in the right direction,” with the business stabilizing after a difficult year and the biggest issue, the large capitated contract, starting to improve meaningfully. She emphasized that the company has tightened labor and costs, is seeing better utilization trends on the contract, and expects that contract to reach a 20% margin by the fourth quarter of next year, excluding any pricing adjustment still under negotiation. Her tone was constructive and operationally focused, with repeated emphasis on simplification, portfolio focus, and returning to predictable performance.
Harriss Currie said Q3 revenue outperformed guidance mainly due to Sleep Health referrals and resupply, while adjusted EBITDA beat the midpoint by $11.2 million thanks to the capitated contract, stronger revenue in other verticals, and cost discipline. He cited headcount of 10,995, down 337 from June, and said net debt ended at $1.85 billion with leverage at 3.05x; unrestricted cash was $80.7 million. He also noted that the company redeemed its 6.25% senior notes due 2028 using proceeds from a $325 million delayed draw term loan, lowering debt service by about 17 basis points, and said capital allocation priorities remain leverage reduction, organic growth investment, and selective tuck-ins.
Analysts focused on the new capitated and preferred-provider deals, asking how large they can become and what lessons from Kaiser apply. Management said the two new regional capitation agreements cover 72,000 lives and about $7 million-$8 million of annual revenue, and explained these deals are more like smoother Humana-style contracts than Kaiser’s complex, de novo rollout. Questions also centered on Medline liability, manufacturer rebate/pricing mechanics, and 2027 free cash flow; management said Medline exposure appears limited and market-wide, while the manufacturer agreement includes both a price increase and volume-based discounts, but details are still being negotiated. On cash flow, Currie said the Q4 baseline should be a reasonable starting point for future periods, adjusted for Diabetes Health and normal seasonality.
The call showed multiple signs that the business is stabilizing: organic growth accelerated, the largest capitated contract turned profitable, and management expects continued margin improvement into 2027. AdaptHealth also raised revenue and EBITDA guidance, added new capitated and enterprise relationships, and highlighted strong digital engagement, including more than 615,000 MyAPP users and a high conversion rate on its AI mask-fitting tool.
The company still faces meaningful moving pieces: the largest capitated contract remains below target today, the manufacturer price increase is not fully resolved, and Medline-related repair/replacement work could create some short-term disruption. Full-year free cash flow guidance was cut, the Diabetes Health sale still has not closed, and management noted about $30 million of stranded overhead remains after the transaction.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 63.3%
- Shares Outstanding
- 136.53M
- Float Shares
- 86.47M
of shares held by institutions
254 13F filers
Buy/sell ratio 5.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AHCO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Susie LeeHouse · NV03 | Sell | Nov 30, 22 | Filing → |
| Kevin HernHouse · OK01 | Sell | Apr 1, 22 | Filing → |
| Kevin HernHouse · OK01 | Sell | Apr 22, 22 | Filing → |
| Kevin HernHouse · OK01 | Buy | May 20, 21 | Filing → |
| Susie LeeHouse · NV03 | Buy | May 26, 21 | Filing → |
| Susie LeeHouse · NV03 | Buy | Feb 11, 21 | Filing → |
| Susie LeeHouse · NV03 | Buy | Feb 9, 21 | Filing → |
| Susie LeeHouse · NV03 | Buy | Jan 22, 21 | Filing → |
| Susie LeeHouse · NV03 | Buy | Jan 5, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Oep Capital Advisors, L.P. | 16.31M | 0 |
| Blackrock, Inc. | 16.29M | ▲ 228.89K |
| Vanguard Group Inc | 11.77M | ▲ 491.11K |
| Deerfield Management Company, L.P. | 11.48M | 0 |
| Fmr LLC | 10.81M | ▲ 2.93M |
| Skyknight Capital, L.P. | 8.58M | 0 |
| Dimensional Fund Advisors LP | 6.39M | ▼ 1.28M |
| Vanguard Capital Management LLC | 4.85M | ▲ 8.75K |
| State Street Corp | 4.77M | ▲ 135.82K |
| Vanguard Portfolio Management LLC | 3.86M | ▼ 2.56M |
| Paradigm Capital Management Inc/Ny | 3.62M | ▲ 3.50M |
| Kennedy Capital Management LLC | 3.49M | ▲ 1.08M |
Held by 351 ETFs
Biggest fund positions in AHCO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 9, 26 | CURRIE HARRISS T | other | 141,372 |
| Sep 9, 26 | CURRIE HARRISS T | other | 0 |
| Aug 6, 26 | WOLF DALE B | buy | 20,000 |
| Aug 6, 26 | SAMET KENNETH A | buy | 23,500 |
| Aug 6, 26 | WOLF DALE B | buy | 20,000 |
| Aug 7, 26 | WOLF DALE B | buy | 20,000 |
| Jul 1, 26 | Schuster III Russell E. | sell | 11,275 |
| Jun 24, 26 | Williams David Solomon III | other | 18,999 |
| Jun 24, 26 | Weaver Susan T | other | 18,999 |
| Jun 24, 26 | Connors Terence J | other | 18,999 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AHCO coverage
Recent articles, reports, and earnings notes.
No research on AHCO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AHCO report →AdaptHealth Corp. (AHCO) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
What AdaptHealth (AHCO) Said on Its Q3 Earnings Call
defenseworld.net · Nov 5
AdaptHealth Corp. (AHCO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
What AdaptHealth (AHCO) Said on Its Q3 Earnings Call
marketbeat.com · Nov 3
AdaptHealth Corp. Announces Third Quarter 2026 Results
businesswire.com · Nov 3
AdaptHealth Corp. Announces Third Quarter 2026 Earnings Release Date and Conference Call
businesswire.com · Oct 21
Analyzing Precipio (NASDAQ:PRPO) and AdaptHealth (NASDAQ:AHCO)
defenseworld.net · Sep 21
AdaptHealth To Participate in Upcoming Investor Conferences
businesswire.com · Sep 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.